Henry O. Gosebruch, insider at AbbVie

Henry O. Gosebruch Insider Information

EVP of AbbVie

Henry Gosebruch is Executive Vice President, Chief Strategy Officer at AbbVie, responsible for corporate strategy, business development and acquisitions, search and evaluation, alliance management and AbbVie Ventures.

Since joining AbbVie in December 2015, Mr. Gosebruch and his team have completed more than 75 partnering, collaboration, mergers & acquisitions (M&A) and venture transactions to bolster AbbVie’s commercial franchises and pipeline of innovative preclinical and clinical development programs, working closely with AbbVie colleagues globally. 

Prior to joining AbbVie, Mr. Gosebruch was Co-Head of J.P. Morgan’s North American M&A Group based in New York. He worked on numerous complex M&A transactions involving companies in more than 20 countries.

Mr. Gosebruch serves on the board of Aptinyx. He is also member of the Advisory Board for the Life Sciences & Management Program at the University of Pennsylvania. At AbbVie, he is the executive chair of the Asian Leadership Network Employee Resource Group.

What is Henry O. Gosebruch's net worth?

The estimated net worth of Henry O. Gosebruch is at least $2.36 million as of May 16th, 2022. Mr. Gosebruch owns 16,623 shares of AbbVie stock worth more than $2,359,967 as of August 17th. This net worth evaluation does not reflect any other assets that Mr. Gosebruch may own. Learn More about Henry O. Gosebruch's net worth.

How old is Henry O. Gosebruch?

Mr. Gosebruch is currently 49 years old. There are 8 older executives and no younger executives at AbbVie. The oldest executive at AbbVie is Mr. Richard A. Gonzalez, Chairman & CEO, who is 68 years old. Learn More on Henry O. Gosebruch's age.

How do I contact Henry O. Gosebruch?

The corporate mailing address for Mr. Gosebruch and other AbbVie executives is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. AbbVie can also be reached via phone at (847) 932-7900. Learn More on Henry O. Gosebruch's contact information.

Has Henry O. Gosebruch been buying or selling shares of AbbVie?

Henry O. Gosebruch has not been actively trading shares of AbbVie during the last ninety days. Most recently, Henry O. Gosebruch sold 83,960 shares of the business's stock in a transaction on Monday, May 16th. The shares were sold at an average price of $155.00, for a transaction totalling $13,013,800.00. Following the completion of the sale, the executive vice president now directly owns 16,623 shares of the company's stock, valued at $2,576,565. Learn More on Henry O. Gosebruch's trading history.

Who are AbbVie's active insiders?

AbbVie's insider roster includes Carlos Alban (Vice Chairman), Roxanne Austin (Director), Nicholas Donoghoe (SVP), Brian Durkin (VP), Richard Gonzalez (CEO), Henry Gosebruch (EVP), Robert Michael (Vice Chairman), Scott Reents (Sr. VP & CFO ), Timothy Richmond (EVP), Azita Saleki-Gerhardt (EVP), Laura Schumacher (Vice Chairman), Michael Severino (Vice Chairman), Elaine Sorg (SVP), Jeffrey Stewart (EVP), and Carrie Strom (SVP). Learn More on AbbVie's active insiders.

Are insiders buying or selling shares of AbbVie?

During the last year, insiders at the sold shares 18 times. They sold a total of 1,054,001 shares worth more than $147,165,681.47. The most recent insider tranaction occured on May, 23rd when Vice Chairman Michael Severino sold 79,801 shares worth more than $12,041,970.90. Insiders at AbbVie own 0.1 % of the company. Learn More about insider trades at AbbVie.

Information on this page was last updated on 5/23/2022.

Henry O. Gosebruch Insider Trading History at AbbVie

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/16/2022Sell83,960$155.00$13,013,800.0016,623View SEC Filing Icon  
3/1/2022Sell15,000$148.26$2,223,900.00View SEC Filing Icon  
7/29/2019Buy30,000$67.28$2,018,400.0075,763View SEC Filing Icon  
11/29/2018Sell42,450$90.10$3,824,745.0030,350View SEC Filing Icon  
10/30/2017Sell18,300$90.55$1,657,065.0081,287View SEC Filing Icon  
7/31/2017Sell18,000$70.09$1,261,620.0096,074View SEC Filing Icon  
See Full Table

Henry O. Gosebruch Buying and Selling Activity at AbbVie

This chart shows Henry O Gosebruch's buying and selling at AbbVie by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

AbbVie Company Overview

AbbVie logo
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Read More

Today's Range

Now: $141.97
Low: $140.64
High: $142.47

50 Day Range

MA: $146.68
Low: $137.62
High: $154.14

2 Week Range

Now: $141.97
Low: $105.56
High: $175.91

Volume

2,798 shs

Average Volume

5,823,630 shs

Market Capitalization

$251.02 billion

P/E Ratio

20.11

Dividend Yield

3.96%

Beta

0.7